Company’s 36-month beta value is 1.50.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADCT is 77.83M, and currently, short sellers hold a 4.07% ratio of that floaft. The average trading volume of ADCT on November 27, 2024 was 380.77K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ADCT) stock’s latest price update
Adc Therapeutics SA (NYSE: ADCT)’s stock price has soared by 9.36 in relation to previous closing price of 2.03. Nevertheless, the company has seen a gain of 7.77% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-09 that ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham – Investor Relations Ameet Mallik – Chief Executive Officer Pepe Carmona – Chief Financial Officer Lindsay Drucker Mann – Global Chief Financial Officer Conference Call Participants Michael Schmidt – Guggenheim Eric Schmidt – Cantor Fitzgerald Kelly Shi – Jefferies Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.
ADCT’s Market Performance
Adc Therapeutics SA (ADCT) has experienced a 7.77% rise in stock performance for the past week, with a -27.45% drop in the past month, and a -24.23% drop in the past quarter. The volatility ratio for the week is 10.50%, and the volatility levels for the past 30 days are at 9.19% for ADCT. The simple moving average for the past 20 days is -14.58% for ADCT’s stock, with a -38.00% simple moving average for the past 200 days.
Analysts’ Opinion of ADCT
Many brokerage firms have already submitted their reports for ADCT stocks, with Stephens repeating the rating for ADCT by listing it as a “Overweight.” The predicted price for ADCT in the upcoming period, according to Stephens is $6 based on the research report published on November 08, 2024 of the current year 2024.
Guggenheim gave a rating of “Buy” to ADCT, setting the target price at $11 in the report published on March 28th of the current year.
ADCT Trading at -23.12% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.25% of loss for the given period.
Volatility was left at 9.19%, however, over the last 30 days, the volatility rate increased by 10.50%, as shares sank -26.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.85% lower at present.
During the last 5 trading sessions, ADCT rose by +7.77%, which changed the moving average for the period of 200-days by -50.11% in comparison to the 20-day moving average, which settled at $2.60. In addition, Adc Therapeutics SA saw 33.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADCT starting from Redmile Group, LLC, who purchase 400,000 shares at the price of $2.81 back on Jul 01 ’24. After this action, Redmile Group, LLC now owns 15,669,217 shares of Adc Therapeutics SA, valued at $1,124,000 using the latest closing price.
Redmile Group, LLC, the 10% Owner of Adc Therapeutics SA, purchase 400,000 shares at $2.81 during a trade that took place back on Jul 01 ’24, which means that Redmile Group, LLC is holding 12,995,040 shares at $1,124,000 based on the most recent closing price.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -1.97 for the present operating margin
- 0.89 for the gross margin
The net margin for Adc Therapeutics SA stands at -3.02. The total capital return value is set at -0.49. Equity return is now at value -705.53, with -52.00 for asset returns.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated 2.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at -1.93. The interest coverage ratio of the stock is -2.7.
Currently, EBITDA for the company is -146.76 million with net debt to EBITDA at -0.49. When we switch over and look at the enterprise to sales, we see a ratio of 3.87. The receivables turnover for the company is 2.92for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.
Conclusion
In a nutshell, Adc Therapeutics SA (ADCT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
